Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2017

Transgene Announces Financial Calendar for 2018

20171221 Financial calendar 2018 EN

Published 21 December 2017
Categorized as 2017, Press release

Transgene Announces Upcoming Investor Meetings

20171218 PR financial agenda T1 18

Published 18 December 2017
Categorized as 2017, Press release

BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors

BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors

Published 6 December 2017
Categorized as 2017, Invir.IO, Press release

Transgene successfully raises € 14.4 million from U.S. and European investors

PR success ABB Transgene

Published 10 November 2017
Categorized as 2017, Press release

Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017

20171030 PR SITC TG4010

Published 30 October 2017
Categorized as 2017, Press release

First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma

20171026-PR-TG6002

Published 26 October 2017
Categorized as 2017, Press release, TG6002

TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B

20171023 PR post AASLD TG1050 final. docx

Published 23 October 2017
Categorized as 2017, Press release, TG1050

Third Quarter Marked by Progress in Clinical Development and Research

171019 PR Q3-2017 FINAL

Published 19 October 2017
Categorized as 2017, Press release

Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

20171017 PR AASLD TG1050 final

Published 17 October 2017
Categorized as 2017, Press release, TG1050

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Caroline Tosch, et al. Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article Publication

Published 12 October 2017
Categorized as -others, 2017, Publication, TG4010

Posts pagination

Page 1 … Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu